GlobeNewswire 2021-11-22 Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
GlobeNewswire 2021-11-22 Obseva Announces Appointment of Stephanie Brown to its Board of Directors
GlobeNewswire 2021-11-19 Bolt Biotherapeutics Announces Changes to its Board of Directors
GlobeNewswire 2021-11-04 ObsEva Announces Third Quarter 2021 Financial Results and Business Update
GlobeNewswire 2021-10-29 ObsEva Announces Management Change
GlobeNewswire 2021-10-20 ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroi...
GlobeNewswire 2021-10-19 ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scien...
GlobeNewswire 2021-10-13 ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
GlobeNewswire 2021-09-30 ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
GlobeNewswire 2021-09-15 ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of ...
GlobeNewswire 2021-09-07 ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
GlobeNewswire 2021-09-01 Forbion Appoints Nanna Lüneborg as a General Partner
GlobeNewswire 2021-08-05 ObsEva Announces Second Quarter 2021 Financial Results and Business Update
GlobeNewswire 2021-08-04 ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving ...
GlobeNewswire 2021-08-03 ObsEva to Present at Upcoming Investor Conferences
GlobeNewswire 2021-07-27 Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), ...
GlobeNewswire 2021-07-02 ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual...
GlobeNewswire 2021-06-30 ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of...
GlobeNewswire 2021-06-24 ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting
GlobeNewswire 2021-06-10 ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of S...
GlobeNewswire 2021-06-02 ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
GlobeNewswire 2021-05-31 ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meetin...
GlobeNewswire 2021-05-25 ObsEva Announces Proposed Changes to the Composition of its Board of Directors
GlobeNewswire 2021-05-20 ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Tre...
GlobeNewswire 2021-05-12 Pharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer